Catawba Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Catawba Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$307K	Hold	3,260	–	–	0.07%	168
2018 Q1	$264K	Sell	3,260 -40	-1%	-$3.43K	0.06%	180
2017 Q4	$294K	Sell	3,300 -670	-17%	-$58.3K	0.07%	175
2017 Q3	$369K	Sell	3,970 -345	-8%	-$30.5K	0.08%	167
2017 Q2	$392K	Buy	4,315 +160	+4%	+$14.6K	0.09%	164
2017 Q1	$365K	Hold	4,155	–	–	0.08%	186
2016 Q4	$344K	Buy	4,155 +715	+21%	+$61.5K	0.08%	184
2016 Q3	$318K	Buy	+3,440	New	+$324K	0.08%	186
2015 Q3	–	Sell	-2,040	Closed	-$279K	–	239
2015 Q2	$279K	Hold	2,040	–	–	0.07%	201
2015 Q1	$254K	Sell	2,040 -185	-8%	-$19.6K	0.06%	217
2014 Q4	$201K	Buy	+2,225	New	+$185K	0.05%	238

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Catawba Capital Management's BMRN Position: Q2 2018 in Review

Catawba Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2018 at 3,260 shares worth $307K. The position accounts for 0.07% of the portfolio, ranked #168.

Catawba Capital Management first reported a position in BMRN in Q4 2014 and has held it in 11 quarters since. The position peaked at $392K in Q2 2017. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Catawba Capital Management held 3,260 shares of BioMarin Pharmaceuticals worth $307K as of Q2 2018.
Catawba Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2018.
BioMarin Pharmaceuticals made up 0.07% of Catawba Capital Management's portfolio in Q2 2018, its #168 holding.
Catawba Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
Catawba Capital Management's BioMarin Pharmaceuticals position peaked at $392K in Q2 2017.
449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.